Loading...

We've got a brand new version of Simply Wall St! Try it out

Allied Biotech

GTSM:1780
Snowflake Description

Good value with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1780
GTSM
NT$2B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Allied Biotech Corporation manufactures and sells carotenoids under the Altratene brand name in Taiwan and internationally. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
1780 Share Price and Events
7 Day Returns
-2.4%
GTSM:1780
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
19.9%
GTSM:1780
-9.6%
TW Biotechs
17.7%
TW Market
1780 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Allied Biotech (1780) -2.4% -1.3% 3.2% 19.9% 1.5% 67.5%
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 1780 outperformed the Biotechs industry which returned -9.6% over the past year.
  • 1780 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
1780
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Allied Biotech's competitors could be found in our database.

1780 Value

 Is Allied Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Allied Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Allied Biotech.

GTSM:1780 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 11%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:1780
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 20%) (29.32%))
1.387
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.387 * 5.96%)
11%

Discounted Cash Flow Calculation for GTSM:1780 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Allied Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:1780 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 11%)
2020 157.54 Est @ 20.56% 141.93
2021 181.50 Est @ 15.21% 147.31
2022 202.31 Est @ 11.47% 147.93
2023 220.20 Est @ 8.84% 145.06
2024 235.64 Est @ 7.01% 139.85
2025 249.13 Est @ 5.73% 133.20
2026 261.15 Est @ 4.83% 125.80
2027 272.12 Est @ 4.2% 118.09
2028 282.34 Est @ 3.76% 110.39
2029 292.08 Est @ 3.45% 102.88
Present value of next 10 years cash flows NT$1,312.00
GTSM:1780 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$292.08 × (1 + 2.73%) ÷ (11% – 2.73%)
NT$3,628.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$3,628.85 ÷ (1 + 11%)10
NT$1,278.18
GTSM:1780 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$1,312.00 + NT$1,278.18
NT$2,590.18
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$2,590.18 / 94.89
NT$27.3
GTSM:1780 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$27.30
Current discount Discount to share price of NT$18.16
= -1 x (NT$18.16 - NT$27.30) / NT$27.30
33.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Allied Biotech is available for.
Intrinsic value
33%
Share price is NT$18.16 vs Future cash flow value of NT$27.3
Current Discount Checks
For Allied Biotech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Allied Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Allied Biotech's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Allied Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Allied Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:1780 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$1.42
GTSM:1780 Share Price ** GTSM (2019-11-11) in TWD NT$18.16
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Allied Biotech.

GTSM:1780 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:1780 Share Price ÷ EPS (both in TWD)

= 18.16 ÷ 1.42

12.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allied Biotech is good value based on earnings compared to the TW Biotechs industry average.
  • Allied Biotech is good value based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Allied Biotech's expected growth come at a high price?
Raw Data
GTSM:1780 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-9.4%per year
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Allied Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Allied Biotech's assets?
Raw Data
GTSM:1780 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$11.88
GTSM:1780 Share Price * GTSM (2019-11-11) in TWD NT$18.16
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:1780 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:1780 Share Price ÷ Book Value per Share (both in TWD)

= 18.16 ÷ 11.88

1.53x

* Primary Listing of Allied Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Allied Biotech is good value based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess Allied Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Allied Biotech has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1780 Future Performance

 How is Allied Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Allied Biotech, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-9.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Allied Biotech expected to grow at an attractive rate?
  • Allied Biotech's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Allied Biotech's earnings are expected to decrease over the next 1-3 years, this is below the Taiwan, Province of China market average.
  • Unable to compare Allied Biotech's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:1780 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:1780 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -9.4%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:1780 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:1780 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 700 173 134
2019-03-31 728 186 138
2018-12-31 765 160 133
2018-09-30 764 145 124
2018-06-30 763 130 114
2018-03-31 715 103 99
2017-12-31 682 100 71
2017-09-30 645 107 53
2017-06-30 609 113 35
2017-03-31 603 113 29
2016-12-31 574 127 40
2016-09-30 563 126 54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Allied Biotech's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Allied Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:1780 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Allied Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:1780 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 1.42
2019-03-31 1.46
2018-12-31 1.41
2018-09-30 1.31
2018-06-30 1.21
2018-03-31 1.04
2017-12-31 0.75
2017-09-30 0.56
2017-06-30 0.37
2017-03-31 0.31
2016-12-31 0.43
2016-09-30 0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Allied Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Allied Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Allied Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1780 Past Performance

  How has Allied Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Allied Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Allied Biotech has delivered over 20% year on year earnings growth in the past 5 years.
  • Allied Biotech's 1-year earnings growth is less than its 5-year average (17.1% vs 43.2%)
  • Allied Biotech's earnings growth has exceeded the TW Biotechs industry average in the past year (17.1% vs -7.5%).
Earnings and Revenue History
Allied Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Allied Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:1780 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 699.90 134.05 126.83 24.49
2019-03-31 728.13 138.39 133.39 23.58
2018-12-31 765.26 133.48 130.91 24.96
2018-09-30 764.37 123.96 127.30 27.06
2018-06-30 763.48 114.43 123.69 29.16
2018-03-31 715.20 98.63 115.46 30.34
2017-12-31 681.73 71.03 114.21 28.37
2017-09-30 645.28 52.86 126.73 25.91
2017-06-30 608.83 34.69 139.26 23.45
2017-03-31 603.08 28.89 135.06 22.65
2016-12-31 573.63 40.23 132.94 22.70
2016-09-30 562.74 54.33 120.20 24.02
2016-06-30 551.85 68.44 107.45 25.33
2016-03-31 537.98 57.39 111.83 26.43
2015-12-31 524.11 46.34 116.21 27.53
2015-09-30 516.48 29.72 118.45 27.52
2015-06-30 508.85 13.10 120.70 27.51
2015-03-31 491.66 10.06 122.43 26.83
2014-12-31 474.47 7.01 124.17 26.15
2014-09-30 488.03 11.12 122.71 25.63
2014-06-30 501.59 15.22 121.24 25.10
2014-03-31 490.58 10.79 118.32 24.79
2013-12-31 479.58 6.36 115.40 24.49
2013-09-30 473.48 16.59 108.63 23.37
2013-06-30 467.39 26.81 101.87 22.25
2013-03-31 473.15 33.21 99.31 22.05
2012-12-31 478.91 39.61 96.74 21.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Allied Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Allied Biotech used its assets more efficiently than the TW Biotechs industry average last year based on Return on Assets.
  • Allied Biotech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Allied Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Allied Biotech has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1780 Health

 How is Allied Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Allied Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Allied Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Allied Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Allied Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Allied Biotech Company Filings, last reported 4 months ago.

GTSM:1780 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1,126.02 499.76 676.58
2019-03-31 1,126.02 499.76 676.58
2018-12-31 1,133.48 479.91 575.52
2018-09-30 1,133.48 479.91 575.52
2018-06-30 1,087.98 440.07 543.81
2018-03-31 1,106.50 445.14 495.21
2017-12-31 1,067.88 450.22 494.24
2017-09-30 1,067.88 450.22 494.24
2017-06-30 1,039.49 385.37 460.96
2017-03-31 1,041.83 385.53 424.81
2016-12-31 1,041.83 385.53 424.81
2016-09-30 1,041.83 385.53 424.81
2016-06-30 1,044.95 395.68 431.03
2016-03-31 1,044.95 395.68 431.03
2015-12-31 1,035.84 405.83 386.57
2015-09-30 1,035.84 405.83 386.57
2015-06-30 1,014.69 424.99 358.87
2015-03-31 1,014.69 424.99 358.87
2014-12-31 991.27 439.11 338.27
2014-09-30 991.27 439.11 338.27
2014-06-30 1,000.26 388.37 313.34
2014-03-31 1,000.26 388.37 313.34
2013-12-31 982.89 373.51 314.31
2013-09-30 982.89 373.51 314.31
2013-06-30 988.86 311.40 304.51
2013-03-31 988.86 311.40 304.51
2012-12-31 980.19 232.47 256.19
  • Allied Biotech's level of debt (44.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (38.9% vs 44.4% today).
  • Debt is well covered by operating cash flow (34.6%, greater than 20% of total debt).
  • Allied Biotech earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Allied Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Allied Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1780 Dividends

 What is Allied Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
5.51%
Current annual income from Allied Biotech dividends.
If you bought NT$2,000 of Allied Biotech shares you are expected to receive NT$110 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Allied Biotech's pays a higher dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.59%).
  • Allied Biotech's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.95%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:1780 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:1780 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-19 1.000 5.562
2019-03-18 1.000 5.731
2018-04-13 0.660 3.666
2017-04-24 0.450 2.522
2016-04-22 0.400 2.203
2016-04-18 0.400 2.089

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Allied Biotech has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Allied Biotech only paid a dividend in the past 4 years.
Current Payout to shareholders
What portion of Allied Biotech's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.4x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Allied Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Allied Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Allied Biotech has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1780 Management

 What is the CEO of Allied Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Qing Hui Lin
CEO Bio

Qing Hui Lin serves as the Chief Executive Officer and Director of Allied Biotech Corporation.

CEO Compensation
  • Insufficient data for Qing Hui to compare compensation growth.
  • Insufficient data for Qing Hui to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Qing Hui Lin

TITLE
Chief Executive Officer and Director
Board of Directors

Rong Min Gong

TITLE
Chairman of the Board

Qing Hui Lin

TITLE
Chief Executive Officer and Director

Guo Bao Chen

TITLE
Director

Hui Jun Liao

TITLE
Director

Zi Kuan Chen

TITLE
Director

Zheng Li Yang

TITLE
Director

Qi Ming Wei

TITLE
Director

Zheng Zhang

TITLE
Director

Yao Ren Zhang

TITLE
Director

Yong Shun Zhuang

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Allied Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Allied Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1780 News

Simply Wall St News

1780 Company Info

Description

Allied Biotech Corporation manufactures and sells carotenoids under the Altratene brand name in Taiwan and internationally. Its products include Beta-carotene, a color pigment, which offers yellow and orange shades that is found in various fruits and vegetables; Apocarotenal that is used as a food colorant, and provides a range of orange to red shades; and Lycopene, a carotenoid, which offers a range of red shades. The company also provides Lutein, a carotenoid that provides a range of yellow shades; Canthaxanthin, which offers a range of orange to red shades; and Co-enzyme Q10, an antioxidant that provides protection from damages caused by free radicals. It serves food, supplement, and feed industries. The company was founded in 2002 and is based in Taipei City, Taiwan.

Details
Name: Allied Biotech Corporation
1780
Exchange: GTSM
Founded: 2002
NT$1,723,198,023
94,889,759
Website: http://www.altratene.com
Address: Allied Biotech Corporation
No. 71, Dunhua South Road,
13th Floor,
Taipei City,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 1780 Common Stock Taipei Exchange TW TWD 29. Apr 2010
Number of employees
Current staff
Staff numbers
0
Allied Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 14:57
End of day share price update: 2019/11/11 00:00
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.